Cambiar Investors LLC Sells 5,880 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Cambiar Investors LLC cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,050 shares of the medical research company’s stock after selling 5,880 shares during the quarter. Cambiar Investors LLC’s holdings in Charles River Laboratories International were worth $7,393,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of CRL. Versant Capital Management Inc boosted its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Wolff Wiese Magana LLC bought a new position in Charles River Laboratories International during the third quarter worth $32,000. Pinnacle Bancorp Inc. boosted its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Assetmark Inc. boosted its stake in Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares in the last quarter. Finally, ORG Wealth Partners LLC bought a new position in Charles River Laboratories International during the fourth quarter worth $56,000. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $159.90 on Tuesday. Charles River Laboratories International, Inc. has a 52-week low of $157.41 and a 52-week high of $275.00. The company has a 50-day simple moving average of $179.79 and a 200 day simple moving average of $192.80. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. The company has a market capitalization of $8.18 billion, a PE ratio of 20.01, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37.

Analysts Set New Price Targets

A number of research analysts have weighed in on CRL shares. The Goldman Sachs Group dropped their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research note on Thursday, January 23rd. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. TD Cowen raised their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating on the stock in a research note on Monday, February 3rd. Three research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $200.79.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).